Hsa_circ_0004674 Promotes Osteosarcoma Doxorubicin Resistance by Regulating the MiR-342-3p/FBN1 Axis

Overview

Journal J Orthop Surg Res

Publisher Biomed Central

Specialty Orthopedics

Date 2021 Aug 19

PMID 34407841

Citations 12

Authors

Yumei Bai

Yanghua Li

Juan Bai

Yumei Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The occurrence of chemoresistance is a common problem in tumor treatment. Circular RNA (circRNA) has been confirmed to be related to tumor chemoresistance. However, the role and the underlying molecular mechanism of hsa_circ_0004674 in the chemoresistance of osteosarcoma (OS) are still unclear.

Methods: The expression of hsa_circ_0004674, miR-342-3p, and fibrillin-1 (FBN1) was determined by qRT-PCR. Cell counting kit 8 assay was used to evaluate the doxorubicin (DXR) resistance of cells. The proliferation and apoptosis of cells were measured using colony formation assay and flow cytometry. Western blot analysis was utilized to examine the protein levels of resistance markers, Wnt/β-catenin pathway markers and FBN1. The interaction between miR-342-3p and hsa_circ_0004674 or FBN1 was confirmed by dual-luciferase reporter assay and RNA pull-down assay. Moreover, animal experiments were performed to assess the effect of hsa_circ_0004674 silencing on the DXR sensitive of OS in vivo.

Results: The upregulated hsa_circ_0004674 was found in DXR-resistant OS tissues and cells. Knockdown of hsa_circ_0004674 could inhibit the DXR resistance of OS cells in vitro and promote the DXR sensitive of OS tumors in vivo. In addition, we discovered that hsa_circ_0004674 could sponge miR-342-3p, and miR-342-3p could target FBN1. MiR-342-3p inhibitor could reverse the inhibition effect of hsa_circ_0004674 knockdown on the DXR resistance of OS cells. Similarly, the suppressive effect of miR-342-3p on the DXR resistance of OS cells also could be reversed by FBN1 overexpression. Furthermore, we revealed that hsa_circ_0004674 silencing inhibited the activity of Wnt/β-catenin pathway by the miR-342-3p/FBN1 axis.

Conclusion: Hsa_circ_0004674 facilitated the DXR resistance of OS through Wnt/β-catenin pathway via regulating the miR-342-3p/FBN1 axis, suggesting that hsa_circ_0004674 was a promising target for the chemoresistance of OS.

Citing Articles

The role of circRNAs in resistance to doxorubicin.

Sanati M, Ghafouri-Fard S Cell Commun Signal. 2024; 22(1):572.

PMID: 39614315 PMC: 11607985. DOI: 10.1186/s12964-024-01952-9.

Hsa_circ_0078767 Enhances Osteosarcoma Chemoresistance to Doxorubicin Through the Regulation of the miR-188-3p/GPX4 Axis.

Tang Y, He Y, Wu L Pharmgenomics Pers Med. 2024; 17:511-520.

PMID: 39588535 PMC: 11586481. DOI: 10.2147/PGPM.S473702.

Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response.

Hashemi M, Khosroshahi E, Daneii P, Hassanpoor A, Eslami M, Koohpar Z Noncoding RNA Res. 2024; 10:98-115.

PMID: 39351450 PMC: 11440256. DOI: 10.1016/j.ncrna.2024.09.006.

A context-aware deconfounding autoencoder for robust prediction of personalized clinical drug response from cell-line compound screening.

He D, Liu Q, Wu Y, Xie L Nat Mach Intell. 2024; 4(10):879-892.

PMID: 38895093 PMC: 11185412. DOI: 10.1038/s42256-022-00541-0.

Osteosarcoma in a ceRNET perspective.

Mosca N, Alessio N, Di Paola A, Marrapodi M, Galderisi U, Russo A J Biomed Sci. 2024; 31(1):59.

PMID: 38835012 PMC: 11151680. DOI: 10.1186/s12929-024-01049-y.

References

Zhao X, Cai Y, Xu J . Circular RNAs: Biogenesis, Mechanism, and Function in Human Cancers. Int J Mol Sci. 2019; 20(16). PMC: 6720291. DOI: 10.3390/ijms20163926. View

Vilchez V, Turcios L, Marti F, Gedaly R . Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol. 2016; 22(2):823-32. PMC: 4716080. DOI: 10.3748/wjg.v22.i2.823. View

Rivankar S . An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2015; 10(4):853-8. DOI: 10.4103/0973-1482.139267. View

Zhu W, Zhu L, Bao Y, Zhong X, Chen Y, Wu Q . Clinical evaluation of neoadjuvant chemotherapy for osteosarcoma. J BUON. 2019; 24(3):1181-1185. View

Bacci G, Ferrari S, Lari S, Mercuri M, Donati D, Longhi A . Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br. 2002; 84(1):88-92. DOI: 10.1302/0301-620x.84b1.12211. View

Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong F . Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018; 17(1):79. PMC: 5889847. DOI: 10.1186/s12943-018-0827-8. View

Sakai L, Keene D . Fibrillin protein pleiotropy: Acromelic dysplasias. Matrix Biol. 2018; 80:6-13. DOI: 10.1016/j.matbio.2018.09.005. View

Lai X, Gupta S, Schmitz U, Marquardt S, Knoll S, Spitschak A . MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance. Theranostics. 2018; 8(4):1106-1120. PMC: 5817113. DOI: 10.7150/thno.19904. View

Wang Z, Liu Y, Lu L, Yang L, Yin S, Wang Y . Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget. 2015; 6(9):6670-83. PMC: 4466642. DOI: 10.18632/oncotarget.3118. View

10.

Kun-Peng Z, Xiao-Long M, Lei Z, Chun-Lin Z, Jian-Ping H, Tai-Cheng Z . Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics. 2018; 10(10):1327-1346. DOI: 10.2217/epi-2018-0023. View

11.

Zhang S, Liu L, Lv Z, Li Q, Gong W, Wu H . MicroRNA-342-3p Inhibits the Proliferation, Migration, and Invasion of Osteosarcoma Cells by Targeting Astrocyte-Elevated Gene-1 (AEG-1). Oncol Res. 2017; 25(9):1505-1515. PMC: 7841055. DOI: 10.3727/096504017X14886485417426. View

12.

Hughes D, Andersson D . Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet. 2015; 16(8):459-71. DOI: 10.1038/nrg3922. View

13.

Simpson E, Brown H . Understanding osteosarcomas. JAAPA. 2018; 31(8):15-19. DOI: 10.1097/01.JAA.0000541477.24116.8d. View

14.

Du Z, Li F, Wang L, Huang H, Xu S . Regulatory effects of microRNA‑184 on osteosarcoma via the Wnt/β‑catenin signaling pathway. Mol Med Rep. 2018; 18(2):1917-1924. PMC: 6072159. DOI: 10.3892/mmr.2018.9184. View

15.

Sakai L, Keene D, Renard M, De Backer J . FBN1: The disease-causing gene for Marfan syndrome and other genetic disorders. Gene. 2016; 591(1):279-291. PMC: 6639799. DOI: 10.1016/j.gene.2016.07.033. View

16.

Liang Y, Song X, Li Y, Su P, Han D, Ma T . circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. Oncogene. 2019; 38(42):6850-6866. DOI: 10.1038/s41388-019-0926-z. View

17.

Ritter J, Bielack S . Osteosarcoma. Ann Oncol. 2010; 21 Suppl 7:vii320-5. DOI: 10.1093/annonc/mdq276. View

18.

Tacar O, Sriamornsak P, Dass C . Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013; 65(2):157-70. DOI: 10.1111/j.2042-7158.2012.01567.x. View

19.

Liu W, Liu P, Gao H, Wang X, Yan M . Long non-coding RNA PGM5-AS1 promotes epithelial-mesenchymal transition, invasion and metastasis of osteosarcoma cells by impairing miR-140-5p-mediated FBN1 inhibition. Mol Oncol. 2020; 14(10):2660-2677. PMC: 7530781. DOI: 10.1002/1878-0261.12711. View

20.

He P, Xu Y, Wang Z, Sheng B . LncRNA LINC00210 regulated radiosensitivity of osteosarcoma cells via miR-342-3p/GFRA1 axis. J Clin Lab Anal. 2020; 34(12):e23540. PMC: 7755772. DOI: 10.1002/jcla.23540. View